drugset / Trial / NCT01454986
Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of the study is to evaluate the safety, tolerability, PK and PD of a single-dose of ALXN1007 in healthy volunteers.
Timeline
- Start
- 2011-11
- Primary completion
- 2013-08
- Completion
- 2013-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | OLENDALIZUMAB | Monoclonal antibody | 0.06 mg/kg | Intravenous |
| Comparator | OLENDALIZUMAB | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Comparator | OLENDALIZUMAB | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Comparator | OLENDALIZUMAB | Monoclonal antibody | 1 mg/kg | Intravenous |
| Comparator | OLENDALIZUMAB | Monoclonal antibody | 3 mg/kg | Intravenous |
| Comparator | OLENDALIZUMAB | Monoclonal antibody | 6 mg/kg | Intravenous |
| Comparator | OLENDALIZUMAB | Monoclonal antibody | 10 mg/kg | Intravenous |
Indications
No indication recorded.